抑制性肿瘤微环境显着阻碍了免疫疗法治疗实体瘤的功效。在这种情况下，基质细胞，例如肿瘤相关成纤维细胞，会发生变化，包括免疫抑制细胞数量和功能的增加。腺苷是一种促进肿瘤生长的因子，由 ATP 分解产生，并在肿瘤微环境中显着升高。它通过与腺苷受体特异性结合发挥作用，其中 A2A 和 A2B 腺苷受体是免疫抑制的主要驱动因素。本文介绍了各种腺苷受体在不同肿瘤微环境中的作用。本综述重点关注肿瘤微环境的基质细胞和非细胞成分中腺苷受体的功能。此外，我们总结并讨论了腺苷受体拮抗剂联合免疫治疗的最新进展和潜在趋势。版权所有 © 2024 Han、Dong、Hu、Wang 和 Wang。

The suppressive tumour microenvironment significantly hinders the efficacy of immunotherapy in treating solid tumors. In this context, stromal cells, such as tumour-associated fibroblasts, undergo changes that include an increase in the number and function of immunosuppressive cells. Adenosine, a factor that promotes tumour growth, is produced from ATP breakdown and is markedly elevated in the tumour microenvironment. It acts through specific binding to adenosine receptors, with A2A and A2B adenosine receptor being primary drivers of immunosuppression. This paper presents the roles of various adenosine receptors in different tumour microenvironments. This review focus on the function of adenosine receptors in the stromal cells and non-cellular components of the tumour microenvironment. Additionally, we summarize and discuss recent advances and potential trends in using adenosine receptor antagonists combined with immunotherapy.Copyright © 2024 Han, Dong, Hu, Wang and Wang.